Posted by Michael Wonder on 08 Oct 2021
Arcutis submits topical roflumilast cream new drug application to FDA for the treatment of adults and adolescents with plaque psoriasis
4 October 2021 - Roflumilast cream demonstrated statistically significant superiority over vehicle on the primary endpoint of IGA Success and statistically significant improvements in multiple secondary endpoints in pivotal Phase 3 trials.
Arcutis Biotherapeutics today announced it has submitted a new drug application to the U.S. FDA for roflumilast cream for the treatment of mild to severe plaque psoriasis.
